By Dutch Rojas
Novo Nordisk and Eli Lilly are about to start raking in tens of billions of dollars a year on their new obesity drugs, say Wall Street analysts. That’s great news for the drug makers, certainly, but it could be a disaster for the companies and government agencies set to pick up the bill.
SOURCE: 5 reasons ICHRAs could be a an alternative to self-funding | BenefitsPRO
Transitioning a company to a self-funded model isn’t always a silver bullet for employers in the long run. For many organizations, an individual coverage health reimbursement arrangement (ICHRA) is the better solution.
Continue reading 5 Reasons ICHRAs Could Be An Alternative To Self-funding